WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.
Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera's SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies (mAbs) into subcutaneous (SQ) formulations. Comera's SQore platform has been successfully tested with over 40 mAbs, with viscosity reductions of up to 85%. Comera uses the SQore platform to identify the driving forces for high viscosity and select excipients that inhibit attractive protein-protein interactions to lower viscosity.
Robert Mahoney, Ph.D., Chief Scientific Officer at Comera, commented, "The challenge many have faced with SQ delivery is that high-concentration antibody solutions can become viscous, and prone to physical instability, such as aggregation, precipitation, or denaturation. We have been able to successfully reduce the viscosity of a diverse range of monoclonal antibodies, demonstrating the versatility and remarkable capabilities of our SQore platform."
Comera is also presenting data from a preclinical study, previously published in the Journal of Pharmaceutical Sciences, that found that a caffeine excipient reduced viscosity of the monoclonal antibody ipilimumab without any adverse impact on antibody pharmacokinetic properties. The addition of one or more excipients, such as caffeine, selectively interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.
Dr. Mahoney continued, "The data reinforces the strength of our SQore platform in reformulating high-viscosity monoclonal antibody solutions and underscores the potential of caffeine and other core excipients as viscosity-reducing agents for subcutaneous monoclonal antibody formulations. Ultimately, the mission driving our research is to enhance convenience, decrease costs and increase compliance by reformulating therapies for patient-delivered SQ injections."
The presentation, titled "SQore Enabled High Concentration mAb Formulations for Patient-Delivered Subcutaneous Delivery," can be accessed following the event
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.
美國馬薩諸塞州沃伯恩市2023年10月16日(GLOBE NEWSWIRE)--開發新一代生物藥物以提高患者用藥的可及性、安全性和便利性的生命科學公司Comera Life Sciences Holdings, Inc.(納斯達克股票代碼:CMRA)今天將在馬薩諸塞州波士頓市舉行的PODD:Partnerships in Drug Delivery會議上展示Comera SQore平台在皮下單克隆抗體製劑開發方面的能力。
Comera配方董事曾宇宏博士將介紹來自Comera的SQorE平台的數據,該平台旨在將單克隆抗體(mAb)等靜脈注射生物製劑轉化爲皮下(SQ)製劑。Comera的SQore平台已成功通過40多種mAb的測試,粘度降低了85%。Comera使用SQore平台來識別高粘度的驅動力,並選擇抑制誘人的蛋白質-蛋白質相互作用以降低粘度的賦形劑。
Comera首席科學官羅伯特·馬奧尼博士評論說:“許多人在SQ遞送方面面臨的挑戰是,高濃度抗體溶液會變得粘稠,容易出現物理不穩定性,例如聚集、沉澱或變性。我們已經成功地降低了各種單克隆抗體的粘度,這證明了我們的SQorE平台的多功能性和非凡功能。”
Comera還提供了先前發表在《藥物科學雜誌》上的一項臨床前研究的數據,該研究發現,咖啡因賦形劑可以降低單克隆抗體ipilimumab的粘度,而不會對抗體藥代動力學特性產生任何不利影響。添加一種或多種賦形劑,例如咖啡因,會選擇性地中斷分子間相互作用,從而降低高濃度單克隆抗製劑的粘度。
Mahoney博士繼續說:“這些數據增強了我們的SQorE平台在重新配製高粘度單克隆抗體溶液方面的實力,並凸顯了咖啡因和其他核心賦形劑作爲皮下單克隆抗體配方降粘劑的潛力。歸根結底,推動我們研究的使命是通過重新制定患者提供的SQ注射療法,提高便利性,降低成本並提高合規性。”
該演示文稿名爲 “用於患者皮下輸送的 sqorE 支持的高濃度單克隆抗體製劑”,可在活動結束後觀看
關於 Comera 生命科學
Comera Life Sciences引領着一個富有同情心的醫學新時代,正在應用深厚的配方科學和技術知識,將基本生物藥物從靜脈注射(IV)轉變爲皮下(SQ)形式。這種方法的目標是爲患者提供自由的自我注射護理,減少機構依賴,並將患者置於治療方案的中心。